Anti-body Drug Conjugates (ADCs) Workshop
Hyderabad
13th of May 2026
Mumbai
15th of May 2026
Introduction to ADCs
Current ADC trends
Early-stage ADC development
Late-stage ADC development
About the workshop
Antibody-Drug Conjugates (ADCs) are proving to be one of the most promising cancer therapies with more than 100 Antibody-Drug Conjugates (ADCs) currently in different stages of approval. Top global pharma pharma companies have also invested billions of dollars into research and development for ADCs.
As it is future of oncology therapy, it is inevitable that ADCs will be forming a part of the product portfolios of most pharma companies and as any therapy in the nascent stage there is a want of technical know-how and expertise on the subject.
Also, drugs coming off patent are some of the most lucrative revenue prospects for Indian pharma companies. In order to not stay behind in the race, it is very important to identify promising drugs which will go off-patent in the coming years and begin research and development now. Anti-body drug conjugates are already proving to be major revenue generators for the innovators and are shaping the future oncology therapeutics market.
Pro-actively, Treffen Media has collaborated with Dr. Kati Räsänen, who has over 20 years of experience in cancer research and drug discovery, to bring you the first of its kind focussed workshop on Anti-body Drug Conjugates (ADCs) in India
Meet the Workshop Leader:
Kati Räsänen, PhD
Kati Räsänen holds a Master’s degree in Biotechnology and a PhD in Cancer Biology. She has also recently graduated with a Master’s degree in Administrative Sciences, specializing in Leadership Psychology.
After completing her first degree, Kati worked at the Institute of Cancer Research in Sutton, United Kingdom. Following her PhD, she completed her postdoctoral training at the Wistar Institute in Philadelphia. She then transitioned to industry, holding positions as Senior Scientist, Team Leader, and Director at Biosceptre International in Cambridge, UK; Orion Pharma in Finland; and Sotio Biotech in Czechia, respectively.
Kati currently runs her own consulting company, supporting start-ups, biotech, and pharmaceutical companies in drug discovery and development programs. She also conducts due diligence for the in-licensing of assets and technology platforms.
Key topics being covered include
Introduction to ADCs : Antibody, linker, payload & Mechanism of Action
Current ADC trends : Novel formats and payloads
Antibody and ADC discovery
Preclinical in vitro and in vivo models
Early-stage ADC development : PKPD correlations, Toxicology studies, Non-GLP CMC
Late-stage ADC development : Regulatory, IND readiness, GMP, CMC
This workshop is specially tailored for senior pharma professionals working on or planning on venturing into ADCs specially those working on early / discovery ADC departments or programs.
The workshop will be held in Hyderabad on the 13th of May 2026 and in Mumbai on the 15th of May 2026 with in-depth learning modules, round-tables and extensive QnA sessions to demystify and simplify ADCs for you.